Yayın:
Therapeutic effects of beard lichen, Usnea barbata extract against Lactococcus garvieae infection in rainbow trout (Oncorhynchus mykiss)

Basit Görünüm
dc.contributor.authorBilen, Soner
dc.contributor.authorSirtiyah, Abdulwahid Mohammed Almahdi
dc.contributor.authorTerzi, Ertugrul
dc.date.accessioned2026-01-04T12:48:13Z
dc.date.issued2019-04-01
dc.description.abstractIn this study, therapeutic effects of aqueous methanolic extracts of beard lichen (Usnea barbata) against Lactococcus garvieae (ATCC 43921) in rainbow trout (Onchorhynchus mykiss) were investigated. Six different experimental groups [0 mg/100 μL (Control), 4 mg/100 μL, 8 mg/100 μL, 12 mg/100 μL, 6 mg/100 μL florfenicol (positive control), 6 mg/100 μL erythromycin (positive control)] were set up to determine effects of lichen extract on immune responses and survival rate. In the study, superoxide radical production was increased in fish treated with 12 mg beard lichen extract, florfenicol and erythromycin compared to that of control (P < 0.05). Lysozyme activity was generally decreased (P < 0.05) or no differences were observed in all experimental groups compared to that of control (P > 0.05). Myeloperoxidase was significantly increased in all antibiotic treated groups. No differences were observed in liver histology of experimental groups compared to control. Cytokine gene expressions were elevated in all experimental groups compared to that of control (P < 0.05), except IL-1β expression at 10th day sampling time. Other immune related genes (IL-8, TGF- β, IL-12 Beta, TNFα1, IL-10, COX-2, IL-6, TLR5, C3, IGM, MHC-II, iNOS, IgT, IFN1, IFN2, IFN reg) were also elevated in all experimental groups compared to that of control group. The survival rates obtained in 4 mg beard lichen treated group, 8 mg beard lichen treated group and erythromycin treated group were 73.08, 65.38 and 80.77% respectively. Our results suggest that beard lichen methanolic extract could be an effective therapeutic agent to be used against L. garvieae infection in rainbow trout at the dose of 4 mg/17.41 ± 0.3 g body weight/day.
dc.description.urihttps://doi.org/10.1016/j.fsi.2019.01.046
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/30711494
dc.description.urihttps://dx.doi.org/10.1016/j.fsi.2019.01.046
dc.identifier.doi10.1016/j.fsi.2019.01.046
dc.identifier.endpage409
dc.identifier.issn1050-4648
dc.identifier.openairedoi_dedup___::d44c95e9e8b02ace978d4f5ef188fcfc
dc.identifier.orcid0000-0001-9459-8178
dc.identifier.orcid0000-0003-2811-6497
dc.identifier.pubmed30711494
dc.identifier.scopus2-s2.0-85060930186
dc.identifier.startpage401
dc.identifier.urihttps://hdl.handle.net/20.500.12597/37298
dc.identifier.volume87
dc.identifier.wos000464086600044
dc.language.isoeng
dc.publisherElsevier BV
dc.relation.ispartofFish &amp; Shellfish Immunology
dc.rightsCLOSED
dc.subjectFish Diseases
dc.subjectUsnea
dc.subjectDose-Response Relationship, Drug
dc.subjectOncorhynchus mykiss
dc.subjectLactococcus
dc.subjectAnimals
dc.subjectGram-Positive Bacterial Infections
dc.subject.sdg3. Good health
dc.titleTherapeutic effects of beard lichen, Usnea barbata extract against Lactococcus garvieae infection in rainbow trout (Oncorhynchus mykiss)
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Soner Bilen","name":"Soner","surname":"Bilen","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0001-9459-8178"},"provenance":null}},{"fullName":"Abdulwahid Mohammed Almahdi Sirtiyah","name":"Abdulwahid Mohammed Almahdi","surname":"Sirtiyah","rank":2,"pid":null},{"fullName":"Ertugrul Terzi","name":"Ertugrul","surname":"Terzi","rank":3,"pid":{"id":{"scheme":"orcid","value":"0000-0003-2811-6497"},"provenance":null}}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"FOS","value":"0403 veterinary science"},"provenance":null},{"subject":{"scheme":"keyword","value":"Fish Diseases"},"provenance":null},{"subject":{"scheme":"keyword","value":"Usnea"},"provenance":null},{"subject":{"scheme":"keyword","value":"Dose-Response Relationship, Drug"},"provenance":null},{"subject":{"scheme":"keyword","value":"Oncorhynchus mykiss"},"provenance":null},{"subject":{"scheme":"keyword","value":"Lactococcus"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"FOS","value":"0401 agriculture, forestry, and fisheries"},"provenance":null},{"subject":{"scheme":"FOS","value":"04 agricultural and veterinary sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Gram-Positive Bacterial Infections"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null}],"mainTitle":"Therapeutic effects of beard lichen, Usnea barbata extract against Lactococcus garvieae infection in rainbow trout (Oncorhynchus mykiss)","subTitle":null,"descriptions":["In this study, therapeutic effects of aqueous methanolic extracts of beard lichen (Usnea barbata) against Lactococcus garvieae (ATCC 43921) in rainbow trout (Onchorhynchus mykiss) were investigated. Six different experimental groups [0 mg/100 μL (Control), 4 mg/100 μL, 8 mg/100 μL, 12 mg/100 μL, 6 mg/100 μL florfenicol (positive control), 6 mg/100 μL erythromycin (positive control)] were set up to determine effects of lichen extract on immune responses and survival rate. In the study, superoxide radical production was increased in fish treated with 12 mg beard lichen extract, florfenicol and erythromycin compared to that of control (P < 0.05). Lysozyme activity was generally decreased (P < 0.05) or no differences were observed in all experimental groups compared to that of control (P > 0.05). Myeloperoxidase was significantly increased in all antibiotic treated groups. No differences were observed in liver histology of experimental groups compared to control. Cytokine gene expressions were elevated in all experimental groups compared to that of control (P < 0.05), except IL-1β expression at 10th day sampling time. Other immune related genes (IL-8, TGF- β, IL-12 Beta, TNFα1, IL-10, COX-2, IL-6, TLR5, C3, IGM, MHC-II, iNOS, IgT, IFN1, IFN2, IFN reg) were also elevated in all experimental groups compared to that of control group. The survival rates obtained in 4 mg beard lichen treated group, 8 mg beard lichen treated group and erythromycin treated group were 73.08, 65.38 and 80.77% respectively. Our results suggest that beard lichen methanolic extract could be an effective therapeutic agent to be used against L. garvieae infection in rainbow trout at the dose of 4 mg/17.41 ± 0.3 g body weight/day."],"publicationDate":"2019-04-01","publisher":"Elsevier BV","embargoEndDate":null,"sources":["Crossref"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_14cb","label":"CLOSED","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Fish &amp; Shellfish Immunology","issnPrinted":"1050-4648","issnOnline":null,"issnLinking":null,"ep":"409","iss":null,"sp":"401","vol":"87","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::d44c95e9e8b02ace978d4f5ef188fcfc","originalIds":["S1050464819300634","10.1016/j.fsi.2019.01.046","50|doiboost____|d44c95e9e8b02ace978d4f5ef188fcfc","30711494","2912114871"],"pids":[{"scheme":"doi","value":"10.1016/j.fsi.2019.01.046"},{"scheme":"pmid","value":"30711494"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":27,"influence":3.2081307e-9,"popularity":1.5905526e-8,"impulse":20,"citationClass":"C4","influenceClass":"C5","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1016/j.fsi.2019.01.046"}],"license":"Elsevier TDM","type":"Article","urls":["https://doi.org/10.1016/j.fsi.2019.01.046"],"publicationDate":"2019-04-01","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"30711494"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1016/j.fsi.2019.01.046"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/30711494"],"publicationDate":"2019-07-02","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1016/j.fsi.2019.01.046"},{"scheme":"mag_id","value":"2912114871"}],"type":"Article","urls":["https://dx.doi.org/10.1016/j.fsi.2019.01.046"],"refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar

Publications